Last reviewed · How we verify
hydrochlorothiazide, losartan
This combination reduces blood pressure by blocking angiotensin II receptors (losartan) and increasing urinary sodium and water excretion (hydrochlorothiazide).
This combination reduces blood pressure by blocking angiotensin II receptors (losartan) and increasing urinary sodium and water excretion (hydrochlorothiazide). Used for Hypertension, Hypertension with left ventricular hypertrophy, Reduction of cardiovascular mortality in hypertensive patients.
At a glance
| Generic name | hydrochlorothiazide, losartan |
|---|---|
| Sponsor | University Hospital, Strasbourg, France |
| Drug class | Angiotensin II receptor antagonist + thiazide diuretic combination |
| Target | AT1 receptor (losartan); sodium-chloride cotransporter (hydrochlorothiazide) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Losartan is an angiotensin II receptor antagonist that prevents vasoconstriction and aldosterone release, lowering blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, promoting sodium and water excretion and reducing blood volume. Together, they provide complementary antihypertensive effects.
Approved indications
- Hypertension
- Hypertension with left ventricular hypertrophy
- Reduction of cardiovascular mortality in hypertensive patients
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia (losartan component)
- Hypokalemia (hydrochlorothiazide component)
- Hyperuricemia
- Cough
- Headache
Key clinical trials
- ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension (PHASE2)
- Efficacy and Safety of a Single-pill Fixed Combination of Sufficient Losartan/Hydrochlorothiazide in Chinese Hypertensive Patients (PHASE4)
- Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension (PHASE3)
- Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Non-Fasting Conditions (PHASE1)
- Evaluation of the Antihypertensive Effect of Hyzaar(R) and Cognitive Function of Hypertensive Patients (0954A-322) (PHASE3)
- MK0954A-264 Filter Study (0954A-264)(COMPLETED) (PHASE3)
- HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED) (PHASE3)
- Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension (0954A-323) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- hydrochlorothiazide, losartan CI brief — competitive landscape report
- hydrochlorothiazide, losartan updates RSS · CI watch RSS
- University Hospital, Strasbourg, France portfolio CI